Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
volasertib + nintedanib
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Volasertib + nintedanib** is an experimental combination therapy for advanced solid tumors, evaluated in a phase I trial. **Volasertib** is a potent, selective small-molecule inhibitor of Polo-like kinase 1 (PLK1), a key regulator of mitosis, causing cell cycle arrest and apoptosis in cancer cells. **Nintedanib** is an oral, multi-targeted tyrosine kinase inhibitor of VEGFR, FGFR, and PDGFR (triple angiokinase inhibitor), acting as an anti-angiogenic agent. The combination aimed to improve antitumor activity by targeting both tumor cell division and the tumor microenvironment. In clinical studies, the regimen demonstrated a manageable safety profile with preliminary antitumor activity, including stable disease, partial responses, and a complete response in advanced cancer patients who failed prior therapies[1][2][5].
- Other names
- volasertib plus nintedanib
02
Targets
BRD4 (Bromodomain-containing protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)PLK2 (Polo-like kinase 2)PLK3VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on volasertib + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on volasertib + nintedanib.